BACKGROUND: Human immunodeficiency virus-infected patients with treated cryptococcal meningitis who start combination antiretroviral therapy (cART) are at risk of further neurological deterioration, in part caused by paradoxical cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). We hypothesized that C-IRIS is associated with alterations of chemokine receptor expression on T cells and chemokine concentrations in cerebrospinal fluid (CSF) that enhance recruitment of T-helper 1 cells and/or myeloid cells to the central nervous system. METHODS: In a prospective study of 128 human immunodeficiency virus-infected patients with cryptococcal meningitis who received antifungal therapy followed by cART, we examined the proportions of CD4(+) and CD8(+) T cells expressing CCR5 and/or CXCR3, in CSF and whole blood and the concentrations of CXCL10, CCL2, and CCL3 in stored CSF and plasma. RESULTS: The proportion of CD4(+) and CD8(+) T cells expressing CXCR3(+)CCR5(+) and the concentrations of CXCL10, CCL2 and CCL3 were increased in CSF compared with blood at cART initiation (P < .0001). Patients with C-IRIS (n = 26), compared with those with no neurological deterioration (n = 63), had higher CSF ratios of CCL2/CXCL10 and CCL3/CXCL10 and higher proportions of CXCR3(+)CCR5(+)CD8(+)T cells in CSF compared with blood at cART initiation (P = .03, .0053, and .02, respectively). CONCLUSION: CD8(+) T-cell and myeloid cell trafficking to the central nervous system may predispose patients to C-IRIS.
BACKGROUND: Human immunodeficiency virus-infectedpatients with treated cryptococcal meningitis who start combination antiretroviral therapy (cART) are at risk of further neurological deterioration, in part caused by paradoxical cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). We hypothesized that C-IRIS is associated with alterations of chemokine receptor expression on T cells and chemokine concentrations in cerebrospinal fluid (CSF) that enhance recruitment of T-helper 1 cells and/or myeloid cells to the central nervous system. METHODS: In a prospective study of 128 human immunodeficiency virus-infectedpatients with cryptococcal meningitis who received antifungal therapy followed by cART, we examined the proportions of CD4(+) and CD8(+) T cells expressing CCR5 and/or CXCR3, in CSF and whole blood and the concentrations of CXCL10, CCL2, and CCL3 in stored CSF and plasma. RESULTS: The proportion of CD4(+) and CD8(+) T cells expressing CXCR3(+)CCR5(+) and the concentrations of CXCL10, CCL2 and CCL3 were increased in CSF compared with blood at cART initiation (P < .0001). Patients with C-IRIS (n = 26), compared with those with no neurological deterioration (n = 63), had higher CSF ratios of CCL2/CXCL10 and CCL3/CXCL10 and higher proportions of CXCR3(+)CCR5(+)CD8(+)T cells in CSF compared with blood at cART initiation (P = .03, .0053, and .02, respectively). CONCLUSION:CD8(+) T-cell and myeloid cell trafficking to the central nervous system may predispose patients to C-IRIS.
Authors: Nalin L Subasinghe; James Lanter; Thomas Markotan; Evan Opas; Sandra McKenney; Carl Crysler; Cuifen Hou; John O'Neill; Dana Johnson; Zhihua Sui Journal: Bioorg Med Chem Lett Date: 2012-12-20 Impact factor: 2.823
Authors: Asna A Siddiqui; Annemarie E Brouwer; Vannaporn Wuthiekanun; Shabbar Jaffar; Robin Shattock; Diane Irving; Joanna Sheldon; Wirongrong Chierakul; Sharon Peacock; Nicholas Day; Nicholas J White; Thomas S Harrison Journal: J Immunol Date: 2005-02-01 Impact factor: 5.422
Authors: Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller Journal: AIDS Date: 2009-02-20 Impact factor: 4.177
Authors: Christina C Chang; Andrew Lim; Saleha Omarjee; Stuart M Levitz; Bernadett I Gosnell; Tim Spelman; Julian H Elliott; William H Carr; Mohamed-Yunus S Moosa; Thumbi Ndung'u; Sharon R Lewin; Martyn A French Journal: J Infect Dis Date: 2013-06-12 Impact factor: 5.226
Authors: Chung-Her Jenh; Mary Ann Cox; Long Cui; Eva-Pia Reich; Lee Sullivan; Shu-Cheng Chen; David Kinsley; Shiguang Qian; Seong Heon Kim; Stuart Rosenblum; Joseph Kozlowski; Jay S Fine; Paul J Zavodny; Daniel Lundell Journal: BMC Immunol Date: 2012-01-10 Impact factor: 3.615
Authors: Vivek Naranbhai; Christina C Chang; Raveshni Durgiah; Saleha Omarjee; Andrew Lim; Mahomed-Yunus S Moosa; Julian H Elliot; Thumbi Ndung'u; Sharon R Lewin; Martyn A French; William H Carr Journal: AIDS Date: 2014-03-13 Impact factor: 4.177
Authors: Peter R Williamson; Joseph N Jarvis; Anil A Panackal; Matthew C Fisher; Síle F Molloy; Angela Loyse; Thomas S Harrison Journal: Nat Rev Neurol Date: 2016-11-25 Impact factor: 42.937
Authors: Darin L Wiesner; Kyle D Smith; Dmitri I Kotov; Judith N Nielsen; Paul R Bohjanen; Kirsten Nielsen Journal: J Immunol Date: 2015-11-20 Impact factor: 5.422
Authors: Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin Journal: Immunol Rev Date: 2013-07 Impact factor: 12.988